Dynamics of brain derived neurotrophic factor when using neuromodulation as part of comprehensive rehabilitation after a stroke
DOI:
https://doi.org/10.12775/JEHS.2025.78.60156Keywords
stroke, brain derived neurotrophic factor, neuromodulation, comprehensive rehabilitationAbstract
The aim of the study was to assess the dynamics of brain derived neurotrophic factor when using neuromodulation.
Material and methods. The study was conducted on the basis of clinical departments of the Medical Institute of the Petro Mohyla Black Sea National University. 140 patients with ischemic stroke were treated. The total sample was randomly divided into 4 clinical groups. Patients in group I (n=30) received standard therapy, which included antithrombotic therapy, antihypertensive drugs, statins, and, according to indications, NSAIDs, antiemetics, insulin and other hypoglycemic drugs, antidepressants, etc. Patients in group II (n=40) received peptidergic compounds (cerebrolysin 40 ml per day) in the acute and long-term periods (a month after discharge). Patients in group III (n=40) received traditional therapy with transcranial micropolarization of the brain. In patients of group IV (n=30) it was used combined neuroprotection in the acute and long-term periods (peptidergic compounds in combination with brain micropolarization).
The level of Brain-Derived Neurotrophic Factor (BDNF) was determined using the enzyme-linked immunosorbent assay (Sigma-Aldrich kit RAB0026, USA) during hospitalization and after 3, 6 and 12 months.
The study was performed in compliance with modern bioethical requirements. All patients signed an informed consent to participate in the study. Statistical analysis performed using analysis of variance using the software Statistica 14.1.25 (TIBCO, USA).
Patients with ischemic stroke were characterized by a decrease in serum BDNF concentration to 10.1±0.3 ng/ml. In all clinical groups, the indicator increased later, with the most pronounced dynamics observed in patients of group IV.
In group I the increment was +44.6%, in group II - +68.3%, in group III - +56.4%, and in group IV - +79.2% with maximum approximation to the reference values.
Conclusions: 1. The use of neuromodulation has a positive effect on the synthesis of neurotrophins. 2. The positive effect of neuromodulation is long-lasting
References
1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3. PMID: 34487721; PMCID: PMC8443449.
2. Liu L, Zhou C, Jiang H, Wei H, Zhou Y, Zhou C, Ji X. Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke. Front Med. 2023 Dec;17(6):1047-1067. doi: 10.1007/s11684-023-1041-7. Epub 2024 Jan 2. PMID: 38165535.
3. Dokova KG, Feigin VL. Trends in Stroke Burden in Central and Eastern Europe from 1990-2019. Neuroepidemiology. 2022;56(5):333-344. doi: 10.1159/000525880. Epub 2022 Jul 6. PMID: 35793640.
4. Ding Q, Liu S, Yao Y, Liu H, Cai T, Han L. Global, Regional, and National Burden of Ischemic Stroke, 1990-2019. Neurology. 2022 Jan 18;98(3):e279-e290. doi: 10.1212/WNL.0000000000013115. Epub 2021 Dec 15. PMID: 34911748.
5. Chang VA, Tirschwell DL, Becker KJ, Schubert GB, Longstreth WT Jr, Creutzfeldt CJ. Associations Between Measures of Disability and Quality of Life at Three Months After Stroke. J Palliat Med. 2024 Jan;27(1):18-23. doi: 10.1089/jpm.2023.0061. Epub 2023 Aug 16. PMID: 37585623; PMCID: PMC11074430.
6. Gimigliano F. Does time spent in rehabilitation make a difference on activity limitation and impairment in people with stroke? - A Cochrane Review summary with commentary. J Rehabil Med. 2022 Aug 18;54:jrm00315. doi: 10.2340/jrm.v54.3511. PMID: 35980003; PMCID: PMC9422866.
7. Kossi O, Raats J, Wellens J, Duckaert M, De Baets S, Van de Velde D, Feys P. Efficacy of rehabilitation interventions evaluated in common neurological conditions in improving participation outcomes: A systematic review. Clin Rehabil. 2024 Jan;38(1):47-59. doi: 10.1177/02692155231191383. Epub 2023 Jul 28. PMID: 37501621.
8. Lee JS, Lee SJ, Hong JM, Alverne FJAM, Lima FO, Nogueira RG. Endovascular Treatment of Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease. J Stroke. 2022 Jan;24(1):3-20. doi: 10.5853/jos.2021.01375. Epub 2022 Jan 31. PMID: 35135056; PMCID: PMC8829471.
9. Yang JL, Lin CM, Hsu YL. Long-Term Functionality Prediction for First Time Ischemic Middle Cerebral Artery Stroke Patients Receiving Conventional Medical Treatment. Neuropsychiatr Dis Treat. 2022 Feb 17;18:275-288. doi: 10.2147/NDT.S350266. PMID: 35210775; PMCID: PMC8860755.
10. Price C. Neuroprotection in acute ischaemic stroke: reasons for optimism? Lancet Neurol. 2025 Mar;24(3):181-183. doi: 10.1016/S1474-4422(25)00007-9. Epub 2025 Feb 13. PMID: 39956130.
11. Ting WK, Fadul FA, Fecteau S, Ethier C. Neurostimulation for Stroke Rehabilitation. Front Neurosci. 2021 May 14;15:649459. doi: 10.3389/fnins.2021.649459. PMID: 34054410; PMCID: PMC8160247.
12. Chen QM, Yao FR, Sun HW, Chen ZG, Ke J, Liao J, Cai XY, Yu LQ, Wu ZY, Wang Z, Pan X, Liu HY, Li L, Zhang QQ, Ling WH, Fang Q. Combining inhibitory and facilitatory repetitive transcranial magnetic stimulation (rTMS) treatment improves motor function by modulating GABA in acute ischemic stroke patients. Restor Neurol Neurosci. 2021;39(6):419-434. doi: 10.3233/RNN-211195. PMID: 34924405.
13. DeMarco AT, Dvorak E, Lacey E, Stoodley CJ, Turkeltaub PE. An Exploratory Study of Cerebellar Transcranial Direct Current Stimulation in Individuals With Chronic Stroke Aphasia. Cogn Behav Neurol. 2021 Jun 2;34(2):96-106. doi: 10.1097/WNN.0000000000000270. PMID: 34074864; PMCID: PMC8186819.
14. Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29. PMID: 27866120.
15. Heynemann S, Lipworth W, McLachlan SA, Philip J, John T, Kerridge I. Therapeutic misunderstandings in modern research. Bioethics. 2024 Feb;38(2):138-152. doi: 10.1111/bioe.13241. Epub 2023 Dec 19. PMID: 38115678; PMCID: PMC10952669.
16. TIBCO Statistica: quick reference https://docs.tibco.com/pub/stat-dms/13.4.0/doc/pdf/TIB_stat-dms_13.4_quick_ref.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 D. Khramtsov

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 54
Number of citations: 0